Are you age 18 or older and haven’t had a pneumococcal vaccine (pneumonia bacteria)?

Consider The STRIDE-3 Clinical Research Study.

The purpose of the study is to test the safety of an investigational study vaccine against pneumococcal bacteria.

The study is being conducted in collaboration at several clinics in Sweden. The study has been approved by the Swedish Medical Products Agency and Ethical Review Authority.

The study vaccine and study-related tests will be provided at no cost. You may also be reimbursed for your time and travel. The study lasts for 6 months with 2 site visits and 3 phone calls.

For more information, including potential risks and benefits of participation, please contact:

Ewa Karlsson, phone 0732-300 450 or e-mail ewa.karlsson@probare.se 


What is pneumococcal disease?

Pneumococcal disease (Streptococcus pneumoniae) is the main cause of pneumonia and can lead to infections in the blood, brain and other organs. These infections can be life-threatening or cause disability.

Vaccines are important for fighting germs because they help the body defend itself.

What is a clinical trial?

A clinical study is research to learn more about how the body reacts to drugs, vaccines or other medical products.

Most new treatments and vaccines must be tested in clinical trials before they can be approved by the authorities. This is because the authorities want confirmation that the new treatments and vaccines are safe and that they work. If a new treatment or vaccine has not been approved, it is called experimental.

Researchers examine the results of many clinical trials to understand which drugs and vaccines work and how they work. It takes many participants in many studies around the world to advance medical science.

Regulations and policies have been developed to ensure that studies are conducted according to strict scientific and ethical principles. Before a clinical study can begin, the Swedish Medicines Agency and the Ethics Review Authority must approve the study. The aim is to protect the rights, safety and well-being of the participants.

What is the purpose of the study?

In the STR1DE-3 study, an investigational vaccine (V116) is being tested for its ability to protect against pneumococcal disease. The study will compare V116 with PCV20 (pneumococcal 20-valent conjugate vaccine). PCV20 is approved as a vaccine for pneumococcal diseases in some countries.

The purpose of the study is to:

  • Test the safety of the V116.
  • Investigate how well the V116 performs compared to the PCV20.
  • Investigate how well V116 works in adults aged 18-49 compared to adults aged 50-64.
  • Investigate how your body handles V116 in adults under 50 compared to adults over 50.

Who can do this in the study?

You can participate in this study if you are 18 years of age or older and:

  • have not previously received the pneumococcal vaccine or have not received the pneumococcal vaccine since childhood
  • have not tested positive (culture) for pneumococcal disease in the past 3 years
  • are not pregnant or breastfeeding and agree not to breastfeed or become pregnant within 6 weeks of receiving study vaccine. 

There are additional requirements that the study doctor can discuss with you.